Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × poly(I).poly(c12,U) × Gynecologic × Clear all
NCT01312389 2021-11-15

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Abramson Cancer Center at Penn Medicine

Phase 1/2 Terminated
3 enrolled 4 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡